TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrP C

Although autologous human mesenchymal stem cells (hMSCs) are a promising source for regenerative stem cell therapy in chronic kidney disease (CKD), the barriers associated with pathophysiological conditions limit therapeutic applicability to patients. We confirmed that level of cellular prion protei...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Redox biology 2019-04, Vol.22, p.101144
Hauptverfasser:	Yoon, Yeo Min, Kim, SangMin, Han, Yong-Seok, Yun, Chul Won, Lee, Jun Hee, Noh, Hyunjin, Lee, Sang Hun
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biomarkers Cell Proliferation Cytokines - metabolism Disease Models, Animal Humans Inflammation Mediators - metabolism Ischemia - metabolism Ischemia - pathology Ischemia - therapy Membrane Potential, Mitochondrial - drug effects Mesenchymal Stem Cell Transplantation Mesenchymal Stem Cells - drug effects Mesenchymal Stem Cells - metabolism Mesenchymal Stem Cells - ultrastructure Mice Mitochondria - drug effects Mitochondria - metabolism Mitophagy - drug effects PrPC Proteins - metabolism Renal Insufficiency, Chronic - metabolism Renal Insufficiency, Chronic - pathology Taurochenodeoxycholic Acid - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!